# 1 Free fatty acids accelerate β-cell death in type 1 diabetes

2

Emily C. Elliott<sup>1#</sup>, Soumyadeep Sakar<sup>1#</sup>, Lisa Bramer<sup>1</sup>, Meagan Burnet<sup>1</sup>, Young-Mo
Kim<sup>1</sup>, Xiaoyan Yi<sup>2</sup>, Igor L. Estevao<sup>1</sup>, Marian Rewers<sup>3</sup>, Xiaolu A. Cambronne<sup>4</sup>, Kendra
Vehik<sup>5</sup>, Rafael Arrojo e Drigo<sup>6</sup>, Thomas O. Metz<sup>1</sup>, Decio L. Eizirik<sup>2</sup>, Bobbie-Jo M. WebbRobertson<sup>1</sup>, Raghavendra G. Mirmira<sup>7</sup>, Ernesto S. Nakayasu<sup>1,\*</sup>

7

<sup>1</sup>Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA,
 USA.

- <sup>2</sup>ULB Center for Diabetes Research, Medical Faculty, Université Libre de Bruxelles
   (ULB), Brussels, Belgium.
- <sup>3</sup>Barbara Davis Center for Diabetes, School of Medicine, University of Colorado
   Anschutz Medical Campus, Aurora, CO, USA.
- <sup>4</sup>Department of Molecular Biosciences, University of Texas at Austin, Austin, TX, USA.
- <sup>5</sup>Health Informatics Institute, Morsani College of Medicine, University of South Florida,
   Tampa, Florida, USA.
- <sup>6</sup>Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville,
   TN, USA.
- <sup>7</sup>Kovler Diabetes Center and Department of Medicine, The University of Chicago,
   Chicago, IL, USA.
- 21
- 22 #Equally contributing authors.
- 23 \*Correspondence: <u>ernesto.nakayasu@pnnl.gov</u> (to E.S.N.)
- 24
- 25

### 26 Abstract

Type 1 diabetes (T1D) results from autoimmune destruction of the insulin producing 27 pancreatic  $\beta$  cells. The body's lipid metabolism is strongly regulated during this process 28 but there is a need to understand how this regulation contributes to the  $\beta$ -cell death. 29 Here, we show that fatty acids are released from plasma lipoproteins in children during 30 islet autoimmunity, prior to T1D onset. These fatty acids (FFAs) enhanced cytokine-31 mediated apoptosis in cultured insulin-producing cells by downregulating the production 32 of nicotinamide adenosine dinucleotide (NAD) via its salvage pathway, as well as 33 34 deregulated central carbon metabolism and impaired levels of ATP. Downregulation of 35 the NAD salvage pathway and central carbon metabolism enzymes were further observed during T1D development, supporting that the pathways for NAD and energy 36 production are compromised in vivo. Our findings show that fatty acids are released 37 38 during islet autoimmunity, accelerating disease development through impaired NAD metabolism. 39

### 41 Introduction

Type 1 diabetes (T1D) affects an estimated 8.4 million people worldwide and reduces 42 the life expectancy of those affected by over a decade<sup>1-3</sup>. The disease results from the 43 progressive loss of insulin-producing ß cells of the pancreas via an autoimmune 44 response, leading to the inability to control blood glucose levels<sup>4,5</sup>. Selected human 45 leukocyte antigen (HLA) genotypes are risk factors, but only 5% of individuals carrying 46 those genotypes eventually develop T1D<sup>6-8</sup>, suggesting the contribution of additional 47 biotic and environmental factors<sup>9</sup>. The body metabolism may be one of these factors as 48 many of its aspects have been associated with T1D development<sup>9-12</sup>. However, little is 49 known about how specific metabolic pathways mechanistically contribute to disease 50 development. 51

Among the metabolic processes, the body lipid metabolism is one of the most regulated 52 during T1D development<sup>10,12-14</sup>. Plasma lipoproteins are regulated in children even prior 53 to the onset of islet autoimmunity (herein referred to as seroconversion and clinically 54 diagnosed by the appearance of circulating islet autoantibodies)<sup>15</sup>. There is also a 55 decrease in the levels of plasma phosphatidylcholine and triacylglycerols during T1D 56 development<sup>10</sup>. Similarly, in human islets treated with the pro-inflammatory cytokines IL-57 1β and IFN-y that mimic the insulitis environment, there is a decrease in triacylglycerol 58 levels<sup>16</sup>. Other lipids, such as short-chain fatty acids, drive inflammation of the intestine, 59 increases intestinal permeability, and augments the exposure to putative dietary 60 antigens<sup>17</sup>. Conversely, diets enriched in omega-3 fatty acids improve intestinal integrity 61 and reduce the onset of T1D in mice<sup>18,19</sup>. Omega-3-rich diet can also diminish the risk of 62 children to develop islet autoimmunity<sup>20</sup>. Mechanistically, omega-3 fatty acids reduce 63 apoptosis of insulin-producing cells by downregulating the methylation of the ADPRHL2 64 gene and releasing the expression of its product, the anti-apoptotic factor ARH3. 65

66 An open question is how these regulations in the lipid metabolism contribute to T1D development. Here, we hypothesize that downregulations of triacylglycerols (in both 67 plasma and islets) and phosphatidylcholines (in plasma) have a role in β-cell death. To 68 69 test this hypothesis, we first analyzed lipidomics and proteomics data from human plasma and islets to determine possible regulatory mechanisms of these lipid classes. 70 71 We also performed experiments in MIN6 insulin-producing cells and analyzed single-cell 72 transcriptomic data to study the downstream consequences of triacylglycerol and phosphatidylcholine downregulation in T1D development. Our data show a mechanism 73 74 by which lipids accelerate T1D development.

### 76 Material and Methods

## 77 Data from a longitudinal cohort of individuals at high risk of developing T1D

78 TEDDY Study and lipidomics dataset. Six clinical research centers - three in the USA 79 (Colorado, Georgia/Florida, Washington State), and three in Europe (Finland, Germany, and Sweden) participated in a population-based HLA screening of newborns between 80 September 1, 2004 and February 28, 2010<sup>21,22</sup>. The HLA high-risk genotypes identified 81 from the general population (89%) and for infants with a first-degree relative with T1D 82 were previously described<sup>23</sup>. Children enrolled (n=8,676) were prospectively followed 83 84 from three months of age to 15 years with study visits that include a blood draw every 85 three months until four years and every three or six months thereafter depending on autoantibody positivity. A nested-matched case-control study was conducted through 86 risk-set sampling using metadata and autoantibody sample results as of May 31. 2012. 87 as previously detailed<sup>24</sup>. Additional matching by the clinical center, sex, and family 88 history of T1D (general population or first-degree relative) were included as criteria in 89 the selection of controls. The sample selection was determined by the Data 90 Coordinating Center (University of South Florida Health Informatics Institute, Tampa, FL) 91 without the lab knowing the case-control status. The characteristics of the donors are 92 listed in Supplemental Table 1. Plasma lipidomics data were reanalyzed from the 93 datasets described in previous publications<sup>25-27</sup>. The effect of sample analysis order on 94 quantified lipidomics data was removed by applying Systematic Error Removal using 95 Random Forest (SERRF)<sup>28</sup>. All missing values were replaced with "NA", and data were 96 97 log2 transformed. For each time point and lipid combination, a paired t-test, accounting for case-control pairs, was conducted, and a Benjamini-Hochberg false-discovery rate 98 correction was applied to the resulting p-values<sup>29</sup>. 99

### 100 GC-MS analysis

Human islets treated with 50 U/mL human IL-18 + 1000 U/mL human IFN-v (cvtokine 101 cocktail 1 or "CT1") for 24 h were collected as previously described<sup>30</sup>. The Pacific 102 Northwest National Laboratory institutional review board deemed the project to not be 103 104 human subject research and waived full ethical review. The characteristics of the donors are listed in **Supplemental Table 2**. The data from this experiment were subsequently 105 integrated with proteomics and lipidomics data published elsewhere<sup>16,30</sup>. Samples from 106 either these human islets or MIN6 cells treated as described above were submitted to 107 simultaneous metabolite, protein, and lipid extraction (MPLEx)<sup>31</sup>. Metabolites were 108 treated with 30 mg/mL methoxyamine in pyridine for 90 min at 37 °C with shaking, and 109 110 derivatized with N-methyl-N-(trimethylsilyl)trifluoroacetamide (MSTFA) (Sigma-Aldrich) with 1% trimethylchlorosilane (TMCS) (Sigma-Aldrich) at 37 °C with shaking for 30 111 min<sup>32</sup>. Derivatized metabolites were analyzed using an Agilent GC 7890A equipped with 112 113 an HP-5 MS column (30 m × 0.25 mm × 0.25 µm; Agilent Technologies, Santa Clara,

114 CA) and coupled with a single quadrupole MSD 5975C (Agilent Technologies). Samples were injected into a splitless port set at 250°C with an initial oven temperature of 60 °C. 115 After 1 min the temperature was increased to 325°C at a rate of 10°C/min, and finished 116 117 with a 5-min hold at 325 °C. The data files were calibrated with external calibration of 118 fatty acid methyl ester and converted to retention time indexes relative to the elution of the fatty acid methyl esters. Molecules were identified by matching experimental 119 retention indices and/or mass spectra to an in-house augmented version of FiehnLib, 120 11<sup>th</sup> edition. 121 NIST20, Wilev and MS-DIAL databases (https://systemsomicslab.github.io/compms/index.html)<sup>33,34</sup>. Significant differences in 122 123 metabolite relative abundances were determined by Student's *t*-test. The central carbon 124 metabolism pathway was plotted along with each metabolite relative abundance using 125 Vanted<sup>35</sup>.

## 126 Cell culture

MIN6 cells were maintained at 37 °C in a 5% CO<sub>2</sub> atmosphere in DMEM containing 4.5 127 g/L each of D-glucose and L-glutamine, 10% fetal bovine serum, 100 units/mL penicillin, 128 100 µg/mL streptomycin, and 50 µM 2-mercaptoethanol. For cell assay experiments, 129 130 cells were treated at 80% confluency with a cytokine cocktail (CT2: 100 ng/mL mouse IFN-γ: R&D, cat#485-MI-100, 10 ng/mL mouse TNF-α: R&D, Cat#410-MT-010, and 5 131 ng/mL mouse IL-1<sup>β</sup>: R&D, cat #401-ML-005) for 24 h. Cells were treated concurrently 132 with various concentrations of palmitate (Cayman, CAS#10006627), 10 µM NAMPT 133 inhibitor FK866 (MCE, Cat. No.: HY-50876), 200 µM hexokinase inhibitor lonidamine 134 135 (Tocris, Cat. No. 1646), or 100 µM nicotinamide riboside (NR) (MCE, HY-123033A). The concentration of NAMPT inhibitor, hexokinase inhibitor, and NR was determined by a 136 137 dose-response curve, and the concentration with maximum effect was chosen. 138 Palmitate stock was prepared in ethanol and diluted in 0.5% delipidated bovine serum 139 albumin to keep it in solution.

## 140 Proteomics analysis

MIN6 cells were lysed in 50 mM Tris-HCI containing 8 M urea and 10 mM dithiothreitol 141 142 and incubated for 1 h at 37 °C with shaking at 800 rpm. Iodoacetamide was added to a 143 final concentration of 40 mM from a 400-mM stock, and the sample was incubated for 1 144 h in the dark at 21 °C. The reaction mixture was diluted 8-fold with 50 mM Tris-HCl, and 1 M CaCl<sub>2</sub> was added to a final concentration of 1 mM. Proteins were digested 145 146 overnight at room temperature using sequencing-grade trypsin (Promega) at an enzyme-to-protein ratio of 1:50. Digested peptides were desalted by solid-extraction in 147 C18 cartridges (Discovery, 50 mg, Sulpelco) following manufacturer recommendations, 148 and dried in a vacuum centrifuge. Peptides were analyzed using a Waters NanoAquity 149 UPLC system coupled with a Q-Exactive mass spectrometer, as previously described<sup>36</sup>. 150 The data were processed with MaxQuant software (v.1.5.5.)<sup>37</sup> using the mouse 151

152 reference proteome database from UniProt Knowledge Base (downloaded on 08/31/2023). Protein N-terminal acetylation and oxidation of methionine were set as 153 154 variable modifications, while cysteine carbamidomethylation was set as a fixed modification. The software's default mass shift tolerance was used. Statistical analysis 155 and heatmap were done using Perseus<sup>38</sup>. MaxLFQ intensity was used to quantify 156 protein, being log2 transformed, median normalized, and having the missing values 157 were imputed with Gaussian distribution<sup>39</sup>. Student's *t*-test was used to determine 158 statistically different proteins. Functional-enrichment analysis was done for the 159 statistically significant proteins using DAVID<sup>40</sup>, using all the predicted mouse genes as 160 161 the background.

#### 162 Apoptosis, NAD, and ATP assays

Apoptosis, NAD, and ATP levels were measured with Caspase-Glo, NAD/NADH-Glo, 163 164 and CellTiter-Glo® 2.0, respectively, following the manufacturer-provided protocols (Promega Cat# G8092, G9071, and G9242). MIN6 cells were treated with palmitate, 165 FK866, Ionidamine, or NR, and CT2 for 24 h. The appropriate amount of the assay 166 reagent was added to the wells. The contents were gently mixed for 30 s and 167 168 luminescence was read for 3 h every 30-min interval using a plate reader (Synergy HT, BioTek). The time point with the highest signal was selected for analysis. All statistical 169 170 analysis and data visualization were performed using GraphPad Prism 9 (Version 9.4.1 171 (458)).

#### 172 Single cell RNA seq analysis

The raw single-cell RNA-seq data files (FASTQ, 10X Genomics) of human islets<sup>41</sup> were 173 downloaded from the Human Pancreas Analysis Program (HPAP) data portal 174 175 (https://hpap.pmacs.upenn.edu/) and processed with Cell Ranger (v6.1.2). The clinical 176 characteristics of the donors are listed in **Supplementary Table 3**. Data were 177 processed following 10X Genomics recommendations for quality control, read alignment 178 to the reference genome (hg38), barcode processing, and molecule counting. Initial 179 clustering was performed using Seurat software (v4.1.1), followed by decontamination 180 of background mRNA using SoupX (v1.6.1); key genes (INS, GCG, SST, TTR, IAPP, 181 PYY, KRT19, TPH1) representing the major cell types were identified in the initial clustering. The adjusted gene expression counts were further processed in Seurat for 182 additional filtering. Potential doublets were identified and removed using scDblFinder 183 184 (v3.16). Cells were filtered based on the following criteria: nFeature\_RNA > 1,000 and < 9,000, mitochondrial gene percentage < 15%, and nCount < 100,000. Following the 185 steps outlined above, we obtained 91,047 single cells for downstream analysis. 186 Normalization of counts was done using the R package scTransform, which adjusts for 187 188 library size variations per cell. Mitochondrial gene variation was also regressed out, as it 189 indicates cell state. We selected the top 3,000 variable genes to perform principal

component analysis (PCA). Data integration was conducted using Harmony (v0.1.1)
with the top 50 PCA components, accounting for each sample and reagent kit batches
as confounding factors. The integrated components were used to construct a Uniform
Manifold Approximation and Projection (UMAP) embedding of the 91,047 cells. Finally,
cell types were annotated with scSorter (v0.0.2) based on known marker genes.
ExcelChIP-Seg data visualization was performed using IGV software.

196

### 197 Results

## 198 **Pro-inflammatory cytokines induce the release of palmitate in human islets**

We have previously shown that triacylglycerols were consistently downregulated in 3 199 insulitis models: islets from NOD mice in the prediabetic stage, and EndoC-BH1 cells 200 201 and human islets treated with a cocktail of pro-inflammatory cytokines (CT1: 50 U/mL IL-1 $\beta$  and 1000 U/mL IFN-y)<sup>16</sup>. To further study this phenotype, we analyzed our 202 previously published proteomics dataset from the same human islets<sup>30</sup> and found that 203 endothelial lipase LIPG was increased 1.4-fold with CT1 treatment (Fig. 1A), suggesting 204 205 a possible mechanism. A gas chromatography-mass spectrometry analysis of the same human islets treated with CT1 showed that palmitate was increased 1.7-fold with CT1 206 207 treatment (Fig. 1B). These data show that CT1 induces the digestion of TGs into free 208 fatty acids (FFAs).

### 209 Increase of free fatty acid levels in plasma from donors with islet autoimmunity

210 We investigated if TG digestion and fatty acid release also occurs in vivo, during T1D development. As LIPG is a major plasma lipoprotein lipase, we search these signatures 211 212 on the plasma lipidomics data of the nested case-control 1 study (NCC1) from The 213 Environmental Determinants of Diabetes in the Young (TEDDY) study (**Supplemental** 214 **Table 4).** In TEDDY NCC1, samples were collected every 3 months from individuals carrying the high-risk HLA alleles from birth until the age of 6 years. We included data 215 from all 94 children who progressed to clinical T1D and from their matched controls. The 216 217 lipidomics data showed a decrease in the levels of 18 of the 127 phosphatidylcholine 218 species (14%) and 14 of the 100 triacylglycerol species (14%) 3 months post-219 seroconversion (Fig. 2A). The phosphatidylcholine and triacylglycerol intermediate cleavage products lysophosphatidylcholines and diacylglycerols, respectively, displayed 220 221 a downregulation trend with 3 out of their 32 species (10%) significantly reduced (Fig. **2B**). Among the FFAs, 2 and 4 of their 31 species (19%) were upregulated at the time of 222 and 3 months post-seroconversion, respectively (Fig. 2C). The downstream products 223 from FFAs, acyl-carnitines, had 3 and 7 of their 17 species (59%) upregulated at the 224 time of and 3 months post-seroconversion, respectively (Fig. 2C). This suggests that 225

the extent of fatty acid release is higher than the one observed based on FFA abundance alone.

We also examined the abundance of key lipoprotein subunits and lipases in TEDDY NCC1 proteomics data<sup>15</sup>. Apolipoprotein ApoA1 was upregulated pre-seroconversion, whereas ApoA2, ApoB, ApoC1, ApoC2 and ApoC3 were downregulated postseroconversion (**Fig. 2D**). Regarding lipases, the lipoprotein lipase LPL and the hepatic lipase LIPC had similar abundances pre- and post-seroconversion compared to the control group (**Fig. 2D**). LIPG was not detected in the analysis.

Overall, these data suggest a digestion of phosphatidylcholines and triacylglycerols, leading to the release of FFAs. These changes are accompanied by reduction in multiple lipoprotein subunits.

## 237 Palmitate enhances pro-inflammatory cytokine-mediated apoptosis.

238 To study if the FFAs have a role in  $\beta$ -cell death, we measured apoptosis in MIN6 cells treated with a cytokine cocktail (CT2: 100 ng/mL IFN-γ, 10 ng/mL TNF-α, and 5 ng/mL 239 240 IL-1 $\beta$ ) for 24 h in combination with a variety of fatty acids at 400  $\mu$ M: oleate (18:1), 241 stearate (18:0), palmitate (16:0), arachidonate (20:4), linoleate (18:2). docosahexaenoate (22:6) and eicosapentaenoate (20:5). While stearate, palmitate and 242 linoleate had minimal to no effect on MIN6 cells without cytokines, they synergistically 243 244 enhanced the cytokine-mediated apoptosis (Fig. 3A). Conversely, arachidonate and eicosapentaenoate reduced apoptosis in both cells treated or not treated with CT2 (Fig. 245 246 **3A**). As palmitate had the strongest effect and was also released by LIPG in islets, it 247 was chosen for the remaining experiments. We treated MIN6 cells with various 248 concentrations of palmitate (50-800 µM) in combination with CT2 for 24 h and measured 249 apoptosis. The palmitate treatment itself had no effect on  $\beta$ -cell apoptosis up to 400  $\mu$ M, 250 but concentrations as low as 200 µM significantly enhanced the apoptosis induced by 251 CT2 (Fig. 3B). These results showed that FFAs increase cytokine-mediated apoptosis.

## 252 NAMPT as a regulator of FFA-enhanced cytokine-mediated apoptosis

253 To identify possible mechanisms of FFA enhancement of cytokine-mediated apoptosis, 254 we performed a proteomics analysis of MIN6 cells treated with CT2 + 400 µM palmitate, leading to the identification of 6049 proteins (Supplemental Table 5). The CT2 255 treatment itself regulated the levels of 631 proteins (86 upregulated and 545 256 257 downregulated), while the palmitate treatment itself regulated the levels of 262 proteins (10 upregulated and 252 downregulated) (Supplemental Table 6-7). The CT2 + 258 palmitate vs. CT2 comparison resulted in abundance changes of 261 proteins (45 and 259 216 proteins upregulated and downregulated, respectively) (Fig. 3C, Supplemental 260 261 Table 8). A functional-enrichment analysis of this comparison identified 48 pathways to 262 be significantly enriched among the regulated proteins (Fig. 3D). This included

263 metabolic pathways (e.g. oxidative phosphorylation, amino sugar and nucleotide sugar 264 metabolism, insulin signaling pathway), cell-death pathways (e.g. necroptosis, NOD-like 265 receptor signaling pathway) and immune response pathways (e.g. PD-L1 expression, 266 human cytomegalovirus infection).

267 We next investigated possible mechanisms of apoptosis enhancement by the CT2 + palmitate treatment. In the proteomics analysis, the NOD-like receptor signaling 268 269 pathway was the one directly involved in apoptosis among those regulated when 270 comparing CT2 + palmitate vs. CT2 conditions (Fig. 3D). One standout member of this 271 pathway was nicotinamide phosphoribosyltransferase, NAMPT, whose levels were upregulated 4.5-fold in cells treated with CT2 and diminished by 0.6-fold following 272 273 addition of palmitate to the CT2 treatment (Fig. 4A). NAMPT is also the rate-limiting 274 enzyme of the intracellular nicotinamide adenosine dinucleotide (NAD) salvage 275 biosynthesis pathway. To test the role of NAMPT depletion in enhancing CT2-mediated 276 apoptosis, we treated MIN6 cells with its inhibitor FK866 in combination with CT2. The inhibition of NAMPT induced a phenotype similar to that of palmitate-induced 277 enhancement of CT2-mediated apoptosis, which was abolished by supplementing the 278 cells with nicotinamide riboside (NR) (Fig. 4B), a metabolite downstream from NAMPT 279 280 in the NAD salvage pathway. We next measured the levels of NAD in FK866-treated cells, which confirmed that FK866 causes depletion of NAD and that its production was 281 rescued by the addition of NR (Fig. 4C). We treated MIN6 cells with CT2 + palmitate in 282 283 combination with NR and measured both apoptosis and NAD levels. The NR 284 supplementation failed to rescue both the apoptosis enhancement by palmitate (Fig. 285 4D) and the recovery of cellular NAD levels (Fig. 4E). These data show that palmitate enhances cytokine-mediated apoptosis via downregulation of NAMPT and depletion of 286 287 NAD levels. However, NR supplementation fails to rescue the cells from apoptosis, 288 suggesting that additional factors are involved.

# Deregulation of the central carbon metabolism by cytokines + palmitate reduces cellular ATP levels

291 We next investigated possible additional factors that impair NR from rescuing cells from 292 the cytokine-mediated apoptosis enhanced by palmitate. The insulin receptor signaling 293 pathway, which regulates glycolysis, was one of the pathways identified as 294 downregulated in the proteomics analysis comparing the CT2 + palmitate vs. CT2 295 conditions (Fig. 3C). Eight proteins of this pathway were downregulated, including the 296 glycolysis rate-limiting enzyme hexokinase 1 (HK1) (Fig. 5A). In MIN6 cells, the CT2 297 treatment alone decreased the level of HK1 by 1.6-fold, but the combination of CT2 + 298 palmitate reduced the levels of HK1 by 33% (Fig. 5B). To investigate possible consequences of this regulation on central carbon metabolism, we performed a GC-MS 299 300 metabolomics analysis of MIN6 cells treated with the combination of CT2 + palmitate for 301 8 h. The palmitate treatment alone only reduced the levels of lactate (Fig. 5C), while

302 CT2 treatment alone induced a trend for increasing the glycolytic activity with elevated but not significant pyruvate concentration (Fig. 5C). The combined CT2 + palmitate 303 304 treatment led to an increase in phosphoenolpyruvate and reduction in lactate levels compared to the control (Fig. 5C). Downstream, there was an increase in the late TCA 305 306 cycle metabolites  $\alpha$ -ketoglutarate, malate and fumarate comparing the CT2 + palmitate vs. the CT2 alone conditions (Fig. 5C). There is an increase in glutamate and glutamine 307 308 (Fig. 5C), suggesting an overflow from the central carbon metabolism towards the 309 amino acid metabolism.

310 Next, we measured the levels of ATP to determine how these changes in the central 311 carbon metabolism affect energy production. The ATP level was reduced by 8% in cells 312 treated solely with palmitate and by 20% in cells treated with CT2. The CT2 + palmitate 313 treatment reduced ATP by 38% (Fig. 5E), showing that cellular energy production is 314 compromised. To test the role of HK1 in the regulation of the CT2 + palmitate enhanced 315 apoptosis, we treated the cells with the HK1 inhibitor lonidamine. The treatment 316 enhanced the CT2-mediated apoptosis in MIN6 by 1.25-fold (Fig. 5D). However, a 317 similar increase was also observed in cells not treated with cytokines (1.4-fold increase) (Fig. 5D), suggesting that HK1 is not responsible for the enhancement of cytokine-318 319 mediated apoptosis by palmitate. These results show that downregulation of HK1 is not 320 responsible for enhancement of cytokine-mediated apoptosis by palmitate. However, FFA in combination with cytokines affected central carbon metabolism and ATP 321 322 production, which might contribute to the depletion of NAD as the salvage pathway 323 requires ATP.

# 324 Downregulation of the NAD salvage pathway and central carbon metabolism in β 325 cells during T1D development

326 To study if the NAD salvage pathway and central carbon metabolism regulation may occur *in vivo* during T1D development, we analyzed the islet single cell RNA seg data 327 from human donors in different stages of T1D development<sup>42</sup>. These data contained 328 329 quantitative sequencing information from 12,660 β cells, including 4,710 from non-330 diabetic donors, 4,156 from donors with single islet autoantibodies, 2,521 from donors with multiple islet autoantibodies, and 1.273 from donors with T1D. In the NAD salvage 331 332 pathway, we found that NAMPT expression is higher in  $\beta$  cells of non-diabetic donors, 333 and significantly reduced in individuals with single or multiple autoantibodies (Fig. 6A). 334 In central carbon metabolism, there is a downregulation of 12 of the 20 detected 335 transcripts of the glycolytic pathway in  $\beta$  cells in individuals with one or multiple islet 336 autoantibodies (Fig. 6B). After the onset of the disease, the levels of the glycolytic 337 enzymes are slightly higher with the transcripts of 3 enzymes upregulated (Fig. 6B). A similar pattern is observed in the TCA cycle, with the expression of 12 enzymes reduced 338 339 in individuals positive for one or multiple autoantibodies, and 4 enzymes increased after 340 the onset of the disease (Fig. 6C). These results show that the expression of the

components of the NAD salvage pathway, glycolysis, and TCA cycle are downregulated
 in β cells during T1D development, supporting our *in vitro* findings.

343

344

345

## 346 **Discussion**

Our current and previous data<sup>16</sup> show that CT1 reduced the levels of triacylglycerols, 347 which was associated to LIPG upregulation and their digestion into FFAs. In the TEDDY 348 plasma lipidomics data, there is a similar pattern with decrease in triacylglycerols and 349 phosphatidylcholines and an increase in FFAs at 3 months post-seroconversion. 350 351 Although some of the increases in FFA levels are moderate, we found that concentrations as low as 200 µM of palmitate enhances cytokine-mediated apoptosis. 352 Considering that the basal levels of palmitate in plasma are around 145 µM<sup>44</sup>, even 353 354 small changes in FFA concentration might have a deleterious effect when combined with the local pro-inflammatory cytokines present during insulitis in a chronic disease. 355

Regarding specific plasma lipoproteins, ApoA1 and ApoA2 (which were regulated in the 356 proteomics analysis) are major components of HDL and chylomicrons<sup>45</sup>, but LIPG being 357 an HDL lipase<sup>46</sup>, making more likely that high-density lipoprotein (HDL) is involved in the 358 process. HDL is also the particle richest in phospholipids<sup>45</sup>, and is a possible source of 359 360 the phosphatidylcholines digested after seroconversion. Likewise, HDL decreases after seroconversion but returns to basal levels after T1D diagnosis, suggesting a temporary 361 regulation<sup>47</sup>. ApoB was also reduced after seroconversion in our proteomics analysis. 362 This protein has two major isoforms, the full-length ApoB-100, enriched in low-density 363 364 lipoprotein (LDL) and very low-density lipoprotein (VLDL), and ApoB-48, enriched in chylomicrons<sup>45</sup>. Unfortunately, our bottom-up proteomics analysis does not distinguish 365 between the two isoforms. Considering that all three particles are rich in 366 triacylglycerols<sup>45</sup>, each could be the source of the triacylglycerols that are digested after 367 368 seroconversion. During islet autoimmunity, LDL levels remain unaltered but are increased later<sup>47</sup>. 369

Regarding lipases involved in the fatty acid release, LIPG is a cell surface lipoprotein 370 lipase that digests lipids from HDL and facilitates the uptake of fatty acids by cells<sup>43</sup>. 371 LIPG also helps to dock and internalize HDL, LDL, VLDL particles by cells<sup>43</sup>. LIPC is 372 less likely to be involved as its regulation is mainly via transcription<sup>48</sup> and its levels in the 373 proteomics analysis remained unaltered. LPL protein levels also remained unaltered, 374 but its activity might be enhanced by the observed reduction in its inhibitors ApoC1 and 375 376 ApoC3. Low ApoC1 is associated with progression to T1D before the age of 5 years<sup>49</sup>. There is a similar pattern of ApoC1 in the TEDDY NCC1, where its reduction was 377

associate with the development of T1D by the age of 6 years<sup>15</sup>. LIPG and LPL might work sequentially to digest triacylglycerols and phosphatidylcholines, as LIPG mainly cleaves fatty acyl groups at the *sn-1* position into diacylglycerols and lysophosphatidylcholines<sup>43</sup>. These intermediates largely remained unaltered in the process, suggesting that they are being cleaved by the action of additional lipase(s).

- 383 Both LIPG and LPL play relevant roles in inflammation. In macrophages, LIPG mediates toll-like receptors 3 and 4 signaling by repressing and inducing the expression of anti-384 and pro-inflammatory genes, respectively<sup>43</sup>. LPL enhances interferon-y-induced pro-385 inflammatory signaling in endothelial cells<sup>50</sup>. Our results show that released FFAs 386 enhance cytokine-mediated apoptosis in MIN6 cells, which involves the depletion of 387 NAD. Pro-inflammatory cytokines induce an upregulation of the NAD de novo synthesis 388 pathway in human islets<sup>51</sup>. This pathway promotes an efficient inflammatory response 389 by fueling the cell with NAD<sup>52</sup>, and might provide the NAD needed during insulitis. Our 390 data show that the combination of CT2 + palmitate inhibits the NAD salvage pathway, 391 depleting cellular NAD. In the body, the *de novo* synthesis pathway is particularly active 392 in the liver, while other tissues rely mostly on the salvage pathway<sup>53</sup>. This agrees with 393 the strong impact we observed in cells treated with cytokines + palmitate. In 394 395 hepatocytes, palmitate downregulates the expression of NAMPT, leading to apoptosis<sup>54</sup>. However, in contrast to our observations, the hepatocyte apoptosis is reversed by the 396 397 addition of nicotinamide mononucleotide, a metabolite downstream from NAMPT in the NAD salvage pathway<sup>54</sup>. In our experimental condition, the cells are not rescued with 398 NR, another metabolite downstream from NAMPT in the NAD salvage pathway. 399
- We found that the combination of FFAs with cytokines induced major changes cellular 400 central carbon metabolism. The cells treated with cytokines + palmitate had an 401 unproductive accumulation of various glycolytic and TCA cycle intermediates, leading to 402 403 reduction in cellular ATP levels. This might explain the inability to rescue the cells with NR, as both enzymes of the salvage pathway, NAMPT and NMNAT, require ATP to 404 catalyze their reactions. Therefore, the deregulation in central carbon metabolism 405 further aggravates the impairment in the NAD salvage pathway<sup>55</sup>. Overall, our data 406 407 show that inflammation leads to a release in FFAs, which aggravates cytokine-mediated 408 apoptosis. This process was associated with the development of T1D at a young age 409 (<6 years). The mechanism involves depletion of cellular NAD levels by impairing its 410 recycling via the salvage pathway, which is further aggravated by deregulation of central 411 carbon metabolism leading to reduced ATP production.
- 412

## 413 Competing interests

- 414 The authors declare that they have no competing interests.
- 415

#### 416 Acknowledgments

Part of the work was performed in the Environmental Molecular Sciences Laboratory, a 417 418 U.S. DOE national scientific user facility at Pacific Northwest National Laboratory (PNNL) in Richland, WA. Battelle operates PNNL for the DOE under contract DE-AC05-419 420 76RLO01830. This work was supported by the Catalyst Award from the Human Islet 421 Research Network (HIRN) (to E.S.N) (via U24 DK104162) and by National Institutes of 422 Health, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) grants R01 DK138335 (to E.S.N., M.R., B.J.M.W.R and T.O.M.), U01 DK127505 (to 423 E.S.N.), U01 DK127786 (to R.G.M, D.L.E, B.J.M.W.R and T.O.M.), R01 DK060581 (to 424 425 R.G.M.), R01 DK105588 (to R.G.M.) The TEDDY Study is funded by U01 DK63829, 426 U01 DK63861, U01 DK63821, U01 DK63865, U01 DK63863, U01 DK63836, U01 427 DK63790, UC4 DK63829, UC4 DK63861, UC4 DK63821, UC4 DK63865, UC4 DK63863, UC4 DK63836, UC4 DK95300, UC4 DK100238, UC4 DK106955, UC4 428 429 DK112243, UC4 DK117483, U01 DK124166, U01 DK128847, and Contract No. 430 HHSN267200700014C from the NIDDK, National Institute of Allergy and Infectious 431 Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and 432 Human Development (NICHD), National Institute of Environmental Health Sciences (NIEHS), Centers for Disease Control and Prevention (CDC), and JDRF. This work is 433 supported in part by the NIH/NCATS Clinical and Translational Science Awards to the 434 435 University of Florida (UL1 TR000064) and the University of Colorado (UL1 TR002535). The content is solely the responsibility of the authors and does not necessarily 436 represent the official views of the National Institutes of Health. 437

438

### 439 Data availability

440 The TEDDY lipidomics data are available at the Metabolomics Workbench repository 441 under project ID PR000950 and doi 10.21228/M8WM4P. The GC-MS data were 442 uploaded into the Open Science Framework under accession number 86u3m 443 (https://osf.io/86u3m/). The proteomics data were deposited into the MassIVE member of the ProteomeXchange, under 444 repository. accession number а MSV000095733. 445

#### 447 References

- 448 1. Beran, D., et al. A plan to improve global type 1 diabetes epidemiology data.
  449 Lancet Diabetes Endocrinol 11, 154-155 (2023).
- 450 2. Gregory, G.A., *et al.* Global incidence, prevalence, and mortality of type 1 451 diabetes in 2021 with projection to 2040: a modelling study. *Lancet Diabetes* 452 *Endocrinol* **10**, 741-760 (2022).
- 453
  453
  454
  454
  455
  455
  456
  457
  457
  458
  459
  459
  459
  450
  450
  450
  450
  451
  451
  452
  452
  453
  453
  454
  455
  455
  455
  455
  455
  455
  455
  455
  455
  456
  457
  457
  457
  458
  459
  459
  459
  450
  450
  450
  450
  450
  451
  451
  452
  452
  453
  454
  455
  455
  455
  455
  455
  455
  455
  456
  457
  457
  457
  458
  458
  458
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
  450
- 456 4. DiMeglio, L.A., Evans-Molina, C. & Oram, R.A. Type 1 diabetes. *Lancet* **391**, 2449-2462 (2018).
- 458 5. Atkinson, M.A., Eisenbarth, G.S. & Michels, A.W. Type 1 diabetes. *Lancet* **383**, 69-82 (2014).
- 460 6. Veijola, R., et al. HLA-DQB1-defined genetic susceptibility, beta cell autoimmunity, and metabolic characteristics in familial and nonfamilial insulin462 dependent diabetes mellitus. Childhood Diabetes in Finland (DiMe) Study Group.
  463 J Clin Invest 98, 2489-2495 (1996).
- 464 7. Baisch, J.M., *et al.* Analysis of HLA-DQ genotypes and susceptibility in insulin465 dependent diabetes mellitus. *N Engl J Med* **322**, 1836-1841 (1990).
- 8. Sanjeevi, C.B., *et al.* Polymorphic amino acid variations in HLA-DQ are associated with systematic physical property changes and occurrence of IDDM.
  Members of the Swedish Childhood Diabetes Study. *Diabetes* 44, 125-131 (1995).
- 470 9. Rewers, M. & Ludvigsson, J. Environmental risk factors for type 1 diabetes.
  471 *Lancet* 387, 2340-2348 (2016).
- 472 10. Lamichhane, S., *et al.* Dynamics of Plasma Lipidome in Progression to Islet
  473 Autoimmunity and Type 1 Diabetes Type 1 Diabetes Prediction and Prevention
  474 Study (DIPP). *Sci Rep* 8, 10635 (2018).
- 475 11. Ferrara-Cook, C., *et al.* Excess BMI Accelerates Islet Autoimmunity in Older
  476 Children and Adolescents. *Diabetes Care* 43, 580-587 (2020).
- 477 12. Lamichhane, S., *et al.* Dysregulation of secondary bile acid metabolism precedes
  478 islet autoimmunity and type 1 diabetes. *Cell Rep Med* 3, 100762 (2022).
- 479 13. Nelson, A.J., *et al.* Lipid mediators and biomarkers associated with type 1
  480 diabetes development. *JCI Insight* 5(2020).
- 481 14. Diaz Ludovico, I., *et al.* Fatty acid-mediated signaling as a target for developing
  482 type 1 diabetes therapies. *Expert Opin Ther Targets* 27, 793-806 (2023).
- 15. Nakayasu, E.S., *et al.* Plasma protein biomarkers predict the development of
  persistent autoantibodies and type 1 diabetes 6 months prior to the onset of
  autoimmunity. *Cell Rep Med* 4, 101093 (2023).
- 486 16. Sarkar, S., *et al.* Regulation of beta-cell death by ADP-ribosylhydrolase ARH3 via
  487 lipid signaling in insulitis. *Cell Commun Signal* 22, 141 (2024).
- 488 17. Yuan, X., *et al.* Functional and metabolic alterations of gut microbiota in children
  489 with new-onset type 1 diabetes. *Nat Commun* 13, 6356 (2022).
- Bi, X., *et al.* omega-3 polyunsaturated fatty acids ameliorate type 1 diabetes and autoimmunity. *J Clin Invest* **127**, 1757-1771 (2017).

- 492 19. Lo Conte, M., *et al.* A diet enriched in omega-3 PUFA and inulin prevents type 1
  493 diabetes by restoring gut barrier integrity and immune homeostasis in NOD mice.
  494 Front Immunol 13, 1089987 (2022).
- 495 20. Norris, J.M., *et al.* Omega-3 polyunsaturated fatty acid intake and islet
  496 autoimmunity in children at increased risk for type 1 diabetes. *JAMA* 298, 1420497 1428 (2007).
- 498 21. Group, T.S. The Environmental Determinants of Diabetes in the Young (TEDDY)
  499 Study. Ann N Y Acad Sci 1150, 1-13 (2008).
- 50022.Johnson, S.B., et al. The Environmental Determinants of Diabetes in the Young501(TEDDY) study: predictors of early study withdrawal among participants with no502family history of type 1 diabetes. Pediatr Diabetes 12, 165-171 (2011).
- Hagopian, W.A., *et al.* The Environmental Determinants of Diabetes in the Young
  (TEDDY): genetic criteria and international diabetes risk screening of 421 000
  infants. *Pediatr Diabetes* 12, 733-743 (2011).
- 50624.Lee, H.S., et al. Biomarker discovery study design for type 1 diabetes in The507Environmental Determinants of Diabetes in the Young (TEDDY) study. Diabetes508Metab Res Rev 30, 424-434 (2014).
- Li, Q., *et al.* Plasma Metabolome and Circulating Vitamins Stratified Onset Age of
  an Initial Islet Autoantibody and Progression to Type 1 Diabetes: The TEDDY
  Study. *Diabetes* **70**, 282-292 (2021).
- 512 26. Li, Q., *et al.* Longitudinal Metabolome-Wide Signals Prior to the Appearance of a
  513 First Islet Autoantibody in Children Participating in the TEDDY Study. *Diabetes*514 **69**, 465-476 (2020).
- 515 27. Webb-Robertson, B.M., *et al.* Prediction of the development of islet 516 autoantibodies through integration of environmental, genetic, and metabolic 517 markers. *J Diabetes* **13**, 143-153 (2021).
- 518 28. Fan, S., *et al.* Systematic Error Removal Using Random Forest for Normalizing 519 Large-Scale Untargeted Lipidomics Data. *Anal Chem* **91**, 3590-3596 (2019).
- 520 29. Benjamini, Y. & Hochberg, Y. Controlling the False Discovery Rate: A Practical 521 and Powerful Approach to Multiple Testing. *Journal of the Royal Statistical* 522 *Society: Series B (Methodological)* **57**, 289-300 (1995).
- 30. Nakayasu, E.S., *et al.* Comprehensive Proteomics Analysis of Stressed Human
  Islets Identifies GDF15 as a Target for Type 1 Diabetes Intervention. *Cell Metab*31, 363-374 e366 (2020).
- S26 31. Nakayasu, E.S., *et al.* MPLEx: a Robust and Universal Protocol for Single Sample Integrative Proteomic, Metabolomic, and Lipidomic Analyses. *mSystems* 1(2016).
- 529 32. Kim, Y.M., *et al.* Salmonella modulates metabolism during growth under 530 conditions that induce expression of virulence genes. *Mol Biosyst* **9**, 1522-1534 531 (2013).
- 532 33. Hiller, K., *et al.* MetaboliteDetector: comprehensive analysis tool for targeted and
  533 nontargeted GC/MS based metabolome analysis. *Anal Chem* **81**, 3429-3439
  534 (2009).
- 535 34. Kind, T., *et al.* FiehnLib: mass spectral and retention index libraries for 536 metabolomics based on quadrupole and time-of-flight gas chromatography/mass 537 spectrometry. *Anal Chem* **81**, 10038-10048 (2009).

- Junker, B.H., Klukas, C. & Schreiber, F. VANTED: a system for advanced data
  analysis and visualization in the context of biological networks. *BMC Bioinformatics* 7, 109 (2006).
- 541 36. Sarkar, S., *et al.* Regulation of β-cell death by ADP-ribosylhydrolase ARH3 via
   542 lipid signaling in insulitis. *Cell Commun Signal* In press.
- 543 37. Cox, J. & Mann, M. MaxQuant enables high peptide identification rates, 544 individualized p.p.b.-range mass accuracies and proteome-wide protein 545 quantification. *Nat Biotechnol* **26**, 1367-1372 (2008).
- 546 38. Tyanova, S., *et al.* The Perseus computational platform for comprehensive 547 analysis of (prote)omics data. *Nature Methods* **13**, 731-740 (2016).
- 548 39. Tyanova, S., *et al.* The Perseus computational platform for comprehensive 549 analysis of (prote)omics data. *Nat Methods* **13**, 731-740 (2016).
- Huang da, W., Sherman, B.T. & Lempicki, R.A. Systematic and integrative
  analysis of large gene lists using DAVID bioinformatics resources. *Nat Protoc* 4, 44-57 (2009).
- 553 41. Fasolino, M., *et al.* Single-cell multi-omics analysis of human pancreatic islets 554 reveals novel cellular states in type 1 diabetes. *Nat Metab* **4**, 284-299 (2022).
- Kaestner, K.H., Powers, A.C., Naji, A., Consortium, H. & Atkinson, M.A. NIH
  Initiative to Improve Understanding of the Pancreas, Islet, and Autoimmunity in
  Type 1 Diabetes: The Human Pancreas Analysis Program (HPAP). *Diabetes* 68, 1394-1402 (2019).
- 559 43. Yu, J.E., Han, S.Y., Wolfson, B. & Zhou, Q. The role of endothelial lipase in lipid 560 metabolism, inflammation, and cancer. *Histol Histopathol* **33**, 1-10 (2018).
- 44. Persson, X.M., Blachnio-Zabielska, A.U. & Jensen, M.D. Rapid measurement of
  plasma free fatty acid concentration and isotopic enrichment using LC/MS. J *Lipid Res* 51, 2761-2765 (2010).
- 564 45. Bhargava, S., de la Puente-Secades, S., Schurgers, L. & Jankowski, J. Lipids
  565 and lipoproteins in cardiovascular diseases: a classification. *Trends Endocrinol*566 *Metab* 33, 409-423 (2022).
- 567 46. Ishida, T., *et al.* Endothelial lipase is a major determinant of HDL level. *J Clin* 568 *Invest* **111**, 347-355 (2003).
- Aulanni'am, A., *et al.* The early detection of type 1 diabetes mellitus and latent autoimmune diabetes in adults (LADA) through rapid test reverse-flow immunochromatography for glutamic acid decarboxylase 65 kDa (GAD(65)). *Heliyon* 8, e08695 (2022).
- 48. Rufibach, L.E., Duncan, S.A., Battle, M. & Deeb, S.S. Transcriptional regulation
  of the human hepatic lipase (LIPC) gene promoter. *J Lipid Res* 47, 1463-1477
  (2006).
- Hirvonen, M.K., *et al.* Serum APOC1 levels are decreased in young autoantibody
  positive children who rapidly progress to type 1 diabetes. *Sci Rep* 13, 15941
  (2023).
- 579 50. Kota, R.S., Ramana, C.V., Tenorio, F.A., Enelow, R.I. & Rutledge, J.C. Differential 580 effects of lipoprotein lipase on tumor necrosis factor-alpha and interferon-581 gamma-mediated gene expression in human endothelial cells. *J Biol Chem* **280**, 582 31076-31084 (2005).

- 583 51. Garcia-Contreras, M., *et al.* Metabolomics Study of the Effects of Inflammation,
  584 Hypoxia, and High Glucose on Isolated Human Pancreatic Islets. *J Proteome*585 *Res* 16, 2294-2306 (2017).
- 586 52. Minhas, P.S., *et al.* Macrophage de novo NAD(+) synthesis specifies immune 587 function in aging and inflammation. *Nat Immunol* **20**, 50-63 (2019).
- 588 53. Liu, L., *et al.* Quantitative Analysis of NAD Synthesis-Breakdown Fluxes. *Cell* 589 *Metab* **27**, 1067-1080 e1065 (2018).
- 590 54. Penke, M., *et al.* Oleate ameliorates palmitate-induced reduction of NAMPT 591 activity and NAD levels in primary human hepatocytes and hepatocarcinoma 592 cells. *Lipids Health Dis* **16**, 191 (2017).
- 593 55. Mehmel, M., Jovanovic, N. & Spitz, U. Nicotinamide Riboside-The Current State 594 of Research and Therapeutic Uses. *Nutrients* **12**(2020).

595



598



599

**Figure 1**: Profiles of endothelial lipase LIPG (A) and free palmitate (B) in human islets treated with cytokines IL-1β and IFN-γ (CT1) for 24 h. LIPG was measured by proteomics analysis while palmitate by gas chromatography-mass spectrometry analysis. NoCT – untreated control. \*\* Paired Student's *t*-test p ≤ 0.01.

#### 605 Figure 2



606

607 Figure 2 – Plasma lipid and lipoprotein profile on during T1D development. Lipid and protein 608 profiles were obtained from lipidomics and proteomics measurements of the TEDDY nested 609 case-control study 1 (NCC1), which comprises of time point sample collections from children up 610 to the age of 6 years. (A) Heatmap of representative, significant species of phosphatidylcholines 611 (PC) and triacylglycerols (TG). (B) Heatmap of all guantified intermediates of PC and TG, 612 lysophosphatidylcholine (LPC) and diacylglycerol (DG), respectively. (C) Heatmap of 613 representative, significant species of PC and TG digestion products, acyl-carnitines (AC) and (free) fatty acids (FA), respectively. Additional abbreviations: ApoA1 - apolipoprotein A1, ApoA2 614 615 apolipoprotein A2, ApoC1 – apolipoprotein C1, ApoC2 – apolipoprotein C2, ApoC3 – 616 apolipoprotein C3, LIPC – hepatic lipase, LPL – lipoprotein lipase, Pre-SC – pre-seroconversion, 617 Post-SC – post-seroconversion. \*Student's *t*-test  $\leq$  0.05.

618





621

622 Figure 3. Enhancement of cytokine-mediated apoptosis by palmitic acid. (A) MIN6 cells were 623 treated for 24 h with a cytokine cocktail (CT2: 100 ng/mL IFN-y, 10 ng/mL TNF-α, and 5 ng/mL 624 IL-1 $\beta$ ) in combination with various types of fatty acids at a concentration of 400  $\mu$ M: oleate, stearate, palmitate, arachidonate, linoleate, docosahexaenoate, eicosapentaenoate and 625 apoptosis levels measured by caspase 3/7 activity using a luminescent assay. (B) The cells 626 were treated with CT2 in combination with various concentrations of palmitate and apoptosis 627 628 was measured. (C) Heatmap of significant proteins comparing CT2 vs. CT2 + 400  $\mu$ M palmitate. (D) Function enrichment analysis of significant proteins comparing CT2 vs. CT2 + palmitate. 629 630 Additional abbreviations: NoCT - no cytokine treatment control, Eth - ethanol vehicle control. 2-

631 way ANOVA, Šídák's multiple comparisons test: \*p  $\leq$  0.05, \*\* p  $\leq$  0.01, \*\*\* p  $\leq$  0.001, \*\*\*\* p  $\leq$  632 0.0001.



633

634 Figure 4 – Regulation of NAD metabolism in cytokine-mediated apoptosis by palmitate. MIN6 635 cells were treated with cytokine cocktail (CT2: 100 ng/mL IFN-γ, 10 ng/mL TNF-α, and 5 ng/mL 636 IL-1β) in combination with 400 μM palmitate. (A) Levels of NAMPT measured by proteomics 637 analysis. Levels of apoptosis (measured by caspase 3/7 activity) (B) and NAD (C) in cells 638 treated with CT2 in combination with 10 µM NAMPT inhibitor FK866 and 100 µM nicotinamide ribose (NR). Levels of apoptosis (measured by caspase 3/7 activity) (D) and NAD (E) in cells 639 640 treated with CT2 + 400µM palmitate in combination with 100 µM NR. Additional abbreviations: 641 NoCT - no cytokine treatment control, Eth - ethanol vehicle control. 2-way ANOVA, Šídák's multiple comparisons test: \* $p \le 0.05$ , \*\*  $p \le 0.01$ , \*\*\*  $p \le 0.001$ , \*\*\*\*  $p \le 0.0001$ . 642



644 Figure 5 – Regulation of the central carbon metabolism by the cytokine cocktail (CT2: 100 ng/mL IFN-y, 10 ng/mL TNF- $\alpha$ , and 5 ng/mL IL-1 $\beta$ ) + palmitate. (A) Enrichment of palmitate + 645 646 CT2-regulated proteins onto the insulin receptor signaling pathway using IPA. (B) Hexokinase 1 647 HK1 protein level measured by proteomic analysis. Levels of apoptosis (measured by caspase 648 3/7 activity) (C) in MIN6 cells treated with CT2 with or without 400 µM palmitate in combination with 200 µM hexokinase inhibitor lonidamine and 100 µM nicotinamide riboside (NR). (D) Level 649 650 of various metabolites from the central carbon metabolism measured using GC-MS in MIN6 cell 651 treated with CT2 + 400 µM palmitate. (E) Level of ATP measured in MIN6 cell treated with CT2 652 + 400 µM palmitate. Additional abbreviations: NoCT - no cytokine treatment control, Eth ethanol vehicle control. T-test (D), 2-way ANOVA, Šídák's multiple comparisons test (B, C, & E): 653 \*\*  $p \le 0.01$ , \*\*\*  $p \le 0.001$ , \*\*\*\*  $p \le 0.0001$ . 654



655

**Figure 6** – Expression of genes from the NAD salvage pathway, glycolysis/gluconeogenesis and TCA cycle during different stages of type 1 diabetes development. The data were downloaded from the Human Pancreas Analysis Program (HPAP) data portal (https://hpap.pmacs.upenn.edu/) and processed ad described in material and methods. Abbreviations: AAB1+ - individuals seropositive for 1 islet autoantibody, AAB2+ - individuals seropositive for multiple islet autoantibodies, beta –  $\beta$  cells, T1D – type 1 diabetes.